Work

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.4582

Authors: Vaibhav Sahai, Kent A. Griffith, Muhammad Shaalan Beg, Walid Labib Shaib, Devalingam Mahalingam, David Bing Zhen, Dustin A. Deming, Sumi Dey, Mishal Mendiratta-Lala, Mark Zalupski

Institutions: University of Michigan, The University of Texas Southwestern Medical Center, Winship Cancer Institute, Northwestern University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2796947832

Cites:

Cited by: 39

Related to: 10